Trials / Completed
CompletedNCT00021697
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Avanir Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare and evaluate the safety of AVP-923 (dextromethorphan/quinidine) for the treatment of emotional lability in ALS patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVP-923 |
Timeline
- Start date
- 2001-01-01
- Primary completion
- 2002-04-01
- Completion
- 2002-04-01
- First posted
- 2001-08-03
- Last updated
- 2016-07-14
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00021697. Inclusion in this directory is not an endorsement.